Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease by Moffitt, Hilary et al.
Formation of Polyglutamine Inclusions in a Wide Range
of Non-CNS Tissues in the HdhQ150 Knock-In Mouse
Model of Huntington’s Disease
Hilary Moffitt
1, Graham D. McPhail
2, Ben Woodman
1, Carl Hobbs
3, Gillian P. Bates
1*
1Department of Medical and Molecular Genetics, King’s College London School of Medicine, London, United Kingdom, 2Division of Cellular Pathology, Barts and the
London NHS Trust, Royal London Hospital, London, United Kingdom, 3Wolfson Centre for Age-Related Diseases, Kings College London School of Medicine, London,
United Kingdom
Abstract
Background: Huntington’s disease (HD) is an inherited progressive neurodegenerative disorder caused by a CAG repeat
expansion in the ubiquitously expressed HD gene resulting in an abnormally long polyglutamine repeat in the huntingtin
protein. Polyglutamine inclusions are a hallmark of the neuropathology of HD. We have previously shown that inclusion
pathology is also present in the peripheral tissues of the R6/2 mouse model of HD which expresses a small N-terminal
fragment of mutant huntingtin. To determine whether this peripheral pathology is a consequence of the aberrant
expression of this N-terminal fragment, we extend this analysis to the genetically precise knock-in mouse model of HD,
HdhQ150, which expresses mutant mouse huntingtin.
Methodology/Principal Findings: We have previously standardized the CAG repeat size and strain background of the R6/2
and HdhQ150 knock-in mouse models and found that they develop a comparable and widespread neuropathology. To
determine whether HdhQ150 knock-in mice also develop peripheral inclusion pathology, homozygous Hdh
Q150/Q150 mice
were perfusion fixed at 22 months of age, and tissues were processed for histology and immunohistochemistry with the
anti-huntingtin antibody S830. The peripheral inclusion pathology was almost identical to that found in R6/2 mice at 12
weeks of age with minor differences in inclusion abundance.
Conclusions/Significance: The highly comparable peripheral inclusion pathology that is present in both the R6/2 and
HdhQ150 knock-in models of HD indicates that the presence of peripheral inclusions in R6/2 mice is not a consequence of
the aberrant expression of an N-terminal huntingtin protein. It remains to be determined whether peripheral inclusions are
a pathological feature of the human disease. Both mouse models carry CAG repeats that cause childhood disease in
humans, and therefore, inclusion pathology may be a feature of the childhood rather than the adult forms of HD. It is
important to establish the extent to which peripheral pathology causes the peripheral symptoms of HD from the
perspective of a mechanistic understanding and future treatment options.
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Introduction
Huntington’s disease (HD) is an autosomal dominant late-onset
progressive neurodegenerative disorder with a mean age of onset
of 40 years. Symptoms include motor disorders, psychiatric
disturbances, cognitive decline and weight loss. Disease duration
is 15 –20 years and there are no effective disease modifying
treatments [1]. The HD mutation is an expanded CAG repeat in
the HD gene that is translated into a polyglutamine (polyQ) repeat
in the huntingtin (Htt) protein [2]. Unaffected individuals have
(CAG)6–35 repeats, whilst disease causing alleles of (CAG)40 and
above are fully penetrant [3,4]. Age of symptom onset can range
from early childhood to extreme old age with repeats of (CAG)75
and above invariably causing the childhood form of the disease
[4]. Neuropathologically, the disease is characterized by global
brain atrophy [5,6], neuronal cell loss in the striatum, cortex and
other brain regions and the deposition of nuclear and cytoplasmic
polyQ aggregates [7,8].
Mouse models of HD include transgenic mice that express
either N-terminal fragments of, or full-length human Htt, as well
as the genetically precise knock-in models, in which CAG repeats
in the mutant range have been inserted into the mouse HD gene
(Hdh) [9]. The N-terminal fragment models [10,11], develop early
onset HD-related phenotypes with rapid progression which,
especially in the case of the R6/2 mouse, has allowed extensive
complementary analyses and established this model as a screening
tool. We recently conducted a comparison of R6/2 (age 12 weeks)
and homozygous HdhQ150 knock-in (Hdh
Q150/Q150 aged 22
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standardised strain background and CAG repeat size) and found
that both models exhibited widespread and comparable brain
phenotypes. Nuclear inclusions and neuropil aggregates were
distributed throughout all brain regions in both models [13].
Microarray expression profiles from both striatum [14] and
cerebellum (Luthi-Carter and Bates, unpublished data) of the R6/
2 and Hdh
Q150/Q150 mice were highly correlated. We had
attributed these widespread pathologies in the R6/2 mouse brain
to the expression of a small N-terminal fragment of Htt and
therefore were surprised to find that it was also a feature of the
Hdh
Q150/Q150 mice.
We have previously reported that polyQ aggregate pathology,
in the form of nuclear inclusions, is also present in a wide range of
peripheral tissues in the R6/2 mouse [15] including skeletal
muscle and pancreatic islets. Very little is known about whether
HD-related pathologies develop in the peripheral tissues of other
mouse models of HD, although it has recently been reported that
nuclear inclusions are present in the pancreatic islets of the N171-
82Q N-terminal fragment model [16]. The peripheral pathogen-
esis of HD is of interest because a number of HD symptoms, that
could be caused by a peripheral pathology, have been reported
including weight loss [17,18], abnormal skeletal muscle energy
metabolism [19], muscle weakness [20] insulin sensitivity [21] and
mitochondrial abnormalities in lymphocytes [22,23]. In general,
peripheral organs from HD patients have not been collected at post
mortem and, unless amenable to biopsy, are not available for
analysis. To begin to determine whether the peripheral aggregate
pathology present in the R6/2 mice has relevance for the human
disease, we have conducted a comprehensive investigation of the
distribution of polyQ aggregates in the peripheral tissues of the
HdhQ150 knock-in model expressing mutant full length Htt at
endogenous levels. We find an identical distribution in aggregate
pathology between the R6/2 and HdhQ150 models, with only
minor differences in aggregate abundance.
Results
In order to investigate the distribution of inclusions in non-CNS
tissue, 22 month old Hdh
Q150/Q150 mice and littermate controls
were perfusion fixed and organs and tissue were removed
processed and wax embedded. A 12 week old R6/2 mouse plus
wild type littermate was processed alongside for direct comparison.
The 5 mm tissue sections were stained with haematoxylin and
eosin (H&E) for tissue identification and immunostained with the
S830 antibody for the identification of inclusions. Tissues and cell
types in which inclusions were detected are summarised in Table 1
and examples are illustrated in Figure 1, Figure 2, Figure 3,
Figure 4, and Figure 5. Inclusions were only detected in cell nuclei
and in the majority of nuclei there was only one inclusion, but in
some cell types: skeletal muscle fibres, liver hepatocytes and
connective tissue fibroblasts, there were multiple nuclear inclu-
sions, as in the R6/2 model. We noted considerable variation in
the number of nuclear inclusions in the tissues examined between
individual Hdh
Q150/Q150 mice but not in the overall distribution of
inclusions.
Distribution of nuclear inclusions in muscle, liver, and
kidney
Nuclear inclusions were found in the skeletal muscle fibres
(Figure 1A and 1B) of the Hdh
Q150/Q150 mice, with some nuclei
containing up to 3 inclusions. Inclusions were also observed in the
fibroblasts of the muscle connective tissue. In contrast nuclear
inclusions were mostly absent from nuclei of the cardiac muscle
fibres and were only observed in a few discrete patches of muscle
fibres in the heart wall, a pattern that was identical to that
observed in the R6/2 mouse. Nuclear inclusions were also
apparent in fibroblasts in the connective tissue of the adventitia
of larger cardiac blood vessels. Small numbers of inclusions were
noted in the smooth muscle cells (see Figure 4E) of the stomach
wall in a very patchy distribution in both mouse models.
In the liver, nuclear inclusions were found in the hepatocytes
and connective tissue and many of the hepatocyte nuclei had
multiple inclusions in a variety of sizes from 0.2 – 2 mm (Figure 1C
and 1D). The distribution of inclusions in the hepatocytes was not
uniform throughout the liver and staining was patchy. A very small
number of Kupffer cells appeared to have inclusions in the nuclei,
but identification of cell types in unstained tissue is difficult and a
more detailed study will be needed to confirm the identity of these
cells. One intrahepatic bile duct present on a slide of a liver
preparation from the Hdh
Q150/Q150 mice contained inclusions in
the epithelial cells (Figure 1E).
Table 1. Distribution of polyQ inclusions in the peripheral
tissues of HD mouse models.
Tissue/Organ Inclusion – positive cells Hdh
Q150/Q150 R6/2
Heart Cardiac muscle fibres ++
Liver Hepatocytes ++ ++
Bile duct epithelium +
Kidney Tubule/duct epithelial cells ++ ++
Interstitial cells ++ ++
Glomerular cells ++
Adrenal gland Zona glomerulosa ++ +
Zona fasciculate ++ +
Medulla +++ +++
Stomach wall Mucosal glands ++ ++
Submucosal plexus ++ ++
Myenteric plexus ++ ++
Serosal ganglia ++ ++
Smooth muscle fibres ++
Duodenum Submucosal plexus ++ ++
Myenteric plexus ++ ++
Rectum Submucosal plexus ++ ++
Myenteric plexus ++ ++
Smooth muscle fibres ++
Pancreas Endocrine - islets of
Langerhans
++ +++
Exocrine - acinar tissue ++
Skeletal muscle
quadriceps
Muscle fibres ++ ++




Seminal vesicle Glandular Epithelium ++ ++
Coagulation gland Glandular Epithelium ++ ++
Brown fat Adipocytes ++ +
Connective tissue Fibroblasts ++
Tissue/organ distribution of polyQ inclusions in the R6/2 and HdhQ150 knock-in
mouse models of HD. Frequency of inclusion is indicated as follows: + sparse;
++ moderate; +++ abundant.
doi:10.1371/journal.pone.0008025.t001
HD Mice: Non-CNS Pathology
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medulla and papilla, in capsule fibroblasts, other connective tissue,
interstitial cells, the epithelium of the tubules and ducts and in a
few cells of the glomerulus (data not shown). It was not possible to
identify which cell type had inclusions in the glomerulus, they may
have been podocytes or mesangial cells. A more detailed study
would be required to identify the cell type. Overall in the kidney,
inclusions were found in low numbers but the numbers increased
from the cortex to the papillae. The pattern was similar in both
mouse models.
Nuclear inclusions are most prominent in the medulla of
the adrenal glands
The adrenal gland pathology has been well characterised in the
R6/2 mice [15,24]. In the adrenal glands of Hdh
Q150/Q150 mice
(Figure 2A–2G) occasional nuclear inclusions were found in the
fibroblasts of the gland capsule and very sparse nuclear inclusions
in the zona glomerulosa and the zona fasciculata. In contrast there
are many large inclusions in the nuclei of the chromaffin cells of
the medulla. In R6/2 the distribution and numbers of nuclear
inclusions in the connective tissue of the capsule and chromaffin
cells of the medulla are similar but there are noticeably more
nuclear inclusions in the cells of the zona glomerulosa and the
zona fasciculata.
Pancreatic nuclear inclusion pathology is conserved
between the two mouse models, but is not accompanied
by b-cell degranulation in the knock-in mice
In the endocrine pancreas, the principle cell type of the islets of
Langerhans, the b-cells, contained nuclear inclusions (Figure 3A),
but the percentage of cells with inclusions varied considerably
between individual Hdh
Q150/Q150 mice and the overall size and
appearance of the islets were similar to that of the controls
(Figure 3B). Inclusions have been reported in the a-cells and d-cells
of the R6/2 islets [25] but without specialised staining procedures
it was not possible to determine if the other islet cell types also
contained inclusions in the knock-in model. A very small number
of acinar cells of the exocrine pancreas were found to have nuclear
inclusions and we noted inclusions in some cells of the connective
tissue. The distribution of inclusions was similar in both animal
models but the islet cells of R6/2 were smaller and more heavily
stained. We also observed inclusions in epithelial cells of a
pancreatic duct in R6/2, but did not find any ducts in the
Hdh
Q150/Q150 sections examined for comparison. We examined
the ultrastructure appearance of the pancreatic islets of the
Hdh
Q150/Q150 mice (Figure 3C) and found no obvious differences
at the ultrastructural level when compared to control animals
(Figure 3D). This is in contrast to the previously described
ultrastructure of the islets in R6/2 mice [25], in which there was a
depletion in the numbers of b-granules in the b-cells and a
reduction in the numbers of b-cells with a resultant reduction in
the size of the islets, a result that we confirmed in this study
(Figure 3E). The b-cells were small with fewer granules and
organelles and the cytoplasm was denser than normal, suggestive
of cell atrophy. The a-cells and d-cells appeared relatively normal.
Inclusion pathology is present throughout the stomach
wall
We used transverse sections of the stomach wall of the
Hdh
Q150/Q150 mice to investigate inclusion distribution in the
fundus, corpus and pyloric regions of the stomach (Figure 4).
Inclusion distribution was similar in all three regions. As in other
tissues the distribution of inclusions was not uniform but patchy. In
the gastric glands, small inclusions were found in the connective
tissue and in the mucosal cells of the gland neck (Figure 4B).
Larger inclusions were found in the epithelial cells at the gland
base (Figure 4C), but specialised staining would be needed to
establish the specific cell type involved: parietal, APUD or chief
cells. They were also observed in connective tissue cells in the
interstitium and adventitia of large blood vessels of the submucosa.
There were large nuclear inclusions in the ganglionic neurons of
the submucosal plexus (Meissner’s) (Figure 4D) and in the ganglion
neurons of the myenteric (Auerbach’s) plexus (Figure 4F). We also
noted nuclear inclusions in the neurons of a third group of ganglia,
on the outer surface of the muscularis externa located mostly over
the corpus region of the stomach, the serosal ganglia (Figure 4G)
[26]. Nuclear inclusions were also observed in small groups of
smooth muscle cells throughout the muscularis externa (Figure 4E).
A similar distribution of inclusions was found in the R6/2 mouse
model.
In the duodenum inclusions were observed in the ganglion cells
of the myenteric and submucosal plexi and the interstitial
connective tissue in both mouse models (data not shown). A
similar distribution was seen in the rectum and we also observed a
small number of smooth muscle cells with inclusions in the
Figure 1. Nuclear inclusions in the skeletal muscle and liver of
Hdh
Q150/Q150 mice. Nuclear inclusions in longitudinal sections of
quadriceps muscle are present in Hdh
Q150/Q150 (A) but absent from wild-
type (B) mice. Nuclear inclusions are present in hepatocytes from
Hdh
Q150/Q150 (C) but not in those from wild-type (D) mice and are
abundant in an Hdh
Q150/Q150 intrahepatic bile duct (E). The insert shows
a higher magnification of the epithelial cells of the bile duct. Nuclear
inclusions are indicated by arrowheads. Scale bar=20 mm.
doi:10.1371/journal.pone.0008025.g001
HD Mice: Non-CNS Pathology
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and colon were not available for analysis.
Inclusion pathology is comparable in the male and
female reproductive organs of both the HdhQ150 and
R6/2 mouse models
The male reproductive organs of Hdh
Q150/Q150 mice contained
a few cells in the testicular epithelium of the seminiferous tubules
of the testis that had nuclear inclusions, the identity of which needs
to be confirmed by appropriate histological staining. Inclusions
were also noted in the peritubular contractile cells of the tunica
propria. An examination of the seminal vesicles (Figure 5A) from
both mouse models revealed the presence of inclusions in the
glandular epithelial cells. Inclusions were also found in the
glandular epithelial cells of the coagulation gland (dorsocranial
part of the prostate gland) (Figure 5B) in both models. In females,
inclusions were only found in the connective tissue of the oviduct
and the ovarial capsule (tunica albuginea) and interstitium in both
mouse models (data not shown)
Selective inclusion pathology in adipose tissue
To investigate brown fat we examined the sub-clavical fat pads.
A small number of the adipocyte nuclei were found to contain
inclusions in Hdh
Q150/Q150 mice, larger numbers of inclusions were
found in the R6/2 model. We examined the visceral fat pads and
found no inclusions in white fat adipocytes in either mouse model
(data not shown).
Inclusion negative tissues
In addition to the ovaries and white fat already mentioned,
inclusions were not present in any of the layers of the skin or principle
cell types of the spleen in either mouse model. However, we observed
small numbers of nuclear inclusions in connective tissue cells in the
Hdh
Q150/Q150 and R6/2 mice in all tissues examined, including the
fibroblasts of the adventitia of larger blood vessels. Even the tissues
andorgans inwhich the principle celltypes did not contain inclusions,
the connective tissue cells did, for example the myofibroblasts of the
capsule and trabeculae in spleen (Figure 5C) and fibroblasts in
subcutaneous connective tissue of the skin.
Shrinkage/atrophy of organs in the HdhQ150 knock-in
mouse model
Symptomatic HD patients exhibit pronounced weight loss and
muscle atrophy [17,27], phenotypes that are modelled in both the R6/
2a n dHdhQ150 mouse models of HD [10,13,28,29]. Failure to gain
weight begins at approximately 7 weeks of age in R6/2 males and 11
weeks in R6/2 females [28,29] whereas, both male and female
Hdh
Q150/Q150 mice stop gaining weight at approximately 9 months of
age [13]. We have previously determined the extent of organ atrophy
[15] in 12 week old symptomatic R6/2 mice for the heart, liver,
kidneys, testes and skeletal muscle. In order to determine whether
organ atrophy had also occurred in the knock-in model, we compared
the weights of heart, kidney, quadriceps, spleen, liver and testes from
four 22 month old Hdh
Q150/Q150 mice to those of four wild type
littermates (two male and two female in each case) (Table 2). In all
Figure 2. Distribution of nuclear inclusions in the adrenal glands of the Hdh
Q150/Q150 and R6/2 mice. (A) transverse section from an
Hdh
Q150/Q150 mouse illustrating the structure of the adrenal gland. Inclusions present in the outer cortex (B) and inner cortex and medulla (C) from
Hdh
Q150/Q150 mice. Insert in (B) shows an inclusion in a fibroblast from the adrenal capsule. Inclusions are absent from the Hdh
Q150/Q150 wild type
control (D,E). A comparable distribution of inclusions is present in the R6/2 mouse (F,G) except for a greater density of inclusions in the cortex.
Nuclear inclusions are indicated by arrowheads. ZG=zona glomerulosa, ZF=zona fasciculata, M=medulla. Scale bar (A)=100 mm, scale bar (B–
G)=50 mm.
doi:10.1371/journal.pone.0008025.g002
HD Mice: Non-CNS Pathology
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Q150/Q150 mice than
in their wild type littermates. The difference in these values was highly
statistically significant for quadriceps, kidney and testes but did not
reach statistical significance for heart, liver and spleen. At least for liver
and heart, this is most likely due to the small number of animals
studied.
Investigation of muscle fibre morphology
We had previously conducted a relatively detailed analysis of
muscle pathology in the R6/2 mouse and had identified a uniform
reduction in the muscle fibre diameter of the quadriceps muscles
[15]. To investigate whether this is also a feature of Hdh
Q150/Q150
muscles, we measure the bound width (shortest) of all fibres in 10
random micrographs from transverse quadriceps sections stained
with H&E from each mouse. The fibre diameters for each
genotype were pooled Hdh
Q150/Q150, n=881; wild type, n=450.
The mean diameters (6SE) were wild type, 44.36614.46 and
Hdh
Q150/Q150, 35.16612.2 (p,0.001). The same micrographs
were also examined for the percentage of fibres with central nuclei,
the number of small angular fibres (Table 3) and the presence of
split fibres. There were 10% central nuclei in the 22 month old
Hdh
Q150/Q150 mice, which is greater than the normal value (#3%)
and a possible indicator of muscle myopathy [30] and split fibres
were also present. The percentage of angular fibres was within the
normal range and no other evidence for neuropathy was found.
Discussion
Although HD is a neurodegenerative disorder, the HD gene is
ubiquitously expressed, and whilst it is understandable that HD
research is predominantly focussed on the central nervous system
(CNS), evidence is accumulating to suggest that some HD
symptoms may be caused by a peripheral pathology. The
mechanistic role that polyQ inclusions play in the pathogenesis
of HD remains the subject of much debate, however, their
presence is considered to be indicative of pathology. In this study,
we have shown that the distribution of nuclear inclusions in the
peripheral tissues of the R6/2 and HdhQ150 models is almost
identical at end-stage disease and therefore, the peripheral
pathology of these two HD mouse models is highly comparable.
Peripheral pathology was identified in skeletal muscle, heart,
pancreas, adrenal gland, liver, kidney, the gastrointestinal (GI)
tract, brown fat, male reproductive organs and connective tissue.
In most cases, the cell types that are affected are, like neurons,
terminally differentiated. Additional factors that might influence
the propensity to form inclusions in a particular cell type could
include expression level of the R6/2 transcript or Hdh gene, Htt
proteolysis and protein folding and clearance networks. Organ
atrophy was also a feature of both models with the testes exhibiting
the most dramatic weight loss followed by skeletal muscle in both
cases.
Therefore, we have demonstrated that the peripheral pathology
documented in the R6/2 mice is not the result of the aberrant
expression of a small N-terminal fragment of mutant Htt as it is
also present in a genetically precise HD mouse model in which an
expanded CAG repeat has been inserted into the mouse Hdh gene.
This peripheral pathology may be responsible for some of the
phenotypes exhibited by the two mouse models. The nuclear
inclusions that form in brain have recruited many additional
nuclear and cytoplasmic proteins and a detailed analysis of the
Figure 3. Pancreatic pathology in the HdhQ150 mouse model. Nuclear inclusions were present in the pancreatic islets of Hdh
Q150/Q150 mice
(A) and absent from wild-type controls (B). Insert shows higher magnification image of a nucleus containing a single inclusion indicated by arrow.
Electron micrograph showing cytoplasmic detail of b-cells in the islets from an Hdh
Q150/Q150 mouse (C), a wild-type control (D), and an R6/2 mouse (E).
The Hdh
Q150/Q150 b-cell appears normal as compared to the control. The R6/2 b-cell is atrophied and degranulated in comparison. Arrows indicate b-
granules (C–E). Pi=pancreatic islet, NI=nuclear inclusion. Scale bar (A,B)=50 mm, scale bar (C,D)=1 mm, scale bar (E)=2 mm.
doi:10.1371/journal.pone.0008025.g003
HD Mice: Non-CNS Pathology
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e8025proteins that are recruited into inclusions in any one of the
peripheral tissues may shed light on the pathogenic processes.
Whether peripheral pathology has relevance to the human disease
is under investigation but, in general, has yet to be established.
Skeletal muscle atrophy is observed in many HD patients
despite an adequate diet and food intake [27], significant body
weight changes are measurable in early as well as late stage disease
[17] and weight loss has recently been shown to track with CAG
repeat length [18]. The use of a hand-held dynamometer has
recently shown that people with HD have a significant reduction
in lower limb muscle strength to, on average, about half of the
strength of healthy matched controls [20]. The presence of dense
granular deposits, immunoreactive to an anti-huntingtin antibody,
have been found in the muscle of an HD patient, but were absent
from a control sample [31]. Might the pathogenic mechanism that
underlies these symptoms be intrinsic to muscle pathology? We
have previously shown that nuclear inclusions form in the muscle
fibres of R6/2 mice [15] and that the loss of muscle bulk in both
the R6/2 and R6/1 mice is associated with pronounced muscle
fibre atrophy. Perturbations in the R6/2 hypothalamic-pituitary-
adrenal axis suggest that the R6/2 mice develop a Cushing-like
syndrome [24] due to increased glucocorticoid levels, however, we
did not observe the selective type 2 (fast) fibre type atrophy that
this would predict, instead a pronounced uniform atrophy had
occurred. A detailed study by Ribchester et al. also found no
evidence for a myopathy (myofibre necrosis, myophagocytosis,
regeneration, rounded atrophic fibres, fibre hypertrophy and
splitting, centralized nuclei, fibrosis ring fibres, vacuoles or any
sign of inflammation) [32] or for a denervation-like pathology
(angulated atrophic fibres, fibre-type grouping, group atrophy or
target fibres), discounting neuropathic causes until end-stage
disease. Instead, they identified a complex phenotype with R6/2
Figure 4. Inclusion distribution across the stomach wall in the Hdh
Q150/Q150 mice. (A) Transverse section through the stomach wall of an
Hdh
Q150/Q150 mouse showing structural detail. Inclusions were present in the mucus cells in the gastric gland neck (B), the basal cells of the gastric
gland (C), the submucosal ganglia (D), smooth muscle (E), the myenteric ganglia (F), and the serosal ganglia (G) of Hdh
Q150/Q150 but absent from the
wild-type control. A similar distribution was found in R6/2 in comparison to the Hdh
Q150/Q150. Nuclear inclusions are indicated by arrowheads. Scale
bar (A)=100 mm, scale bar (B–G)=20 mm.
doi:10.1371/journal.pone.0008025.g004
HD Mice: Non-CNS Pathology
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Q150/Q150 mice at 22 months of age.
Mean Weight g (6Std. Error)
Independent samples
t-test % Weight of WT % Weight of WT
Organ/Tissue WT 22 month
Hdh
Q150/Q150




R6/2 12 wk previous
study [15]
Quadriceps muscle 0.1760.01 0.0960.01 p,0.001 * 53 42
Heart 0.1860.03 0.1260.01 p=0.152 67 55
Liver 1.4160.12 1.1960.06 p=0.212 84 75
Kidney 0.2260.02 0.1760.02 p=0.031 * 78 50
Spleen 0.1060.00 0.0960.03 p=0.391 90 67
Testes 0.0860.01 0.0360.01 p=0.005 * 38 15
Organs were removed from perfusion fixed 22 month old Hdh
Q150/Q150 mice and their wild type littermate controls (n=4 mice/genotype) and weighed to determine the
extent of organ atrophy. These data are compared to those previously calculated for R6/2 mice at 12 weeks of age as compared to wild type littermates.
*statistically significant.
doi:10.1371/journal.pone.0008025.t002
Figure 5. Inclusions are present in the male reproductive glandular epithelium and spleen connective tissue. Nuclear inclusions were
present in the epithelial cells of the seminal vesicles (A) and the epithelium of the coagulation gland (B) in Hdh
Q150/Q150 but absent from wild-type
mice. A similar distribution was identified in R6/2 mice although the number of affected cells was fewer in number in both cases. Nuclear inclusions
were present in connective tissue cells of the spleen capsule from Hdh
Q150/Q150 mice (C) with a similar distribution in R6/2. Nuclear inclusions are
indicated by arrowheads. Scale bar=20 mm.
doi:10.1371/journal.pone.0008025.g005
Table 3. Analysis of indicators of myopathy and neuropathy in skeletal muscle.
No. Fibres No. Fibres Central Nuclei % Fibres Central Nuclei Total Angular Fibres % Angular Fibres
WT 459 10 2.2 1 0.22
Hdh
Q150/Q150 916 99 10.81 5 0.54
Greater than 3% of central nuclei is considered abnormal and a possible indicator of muscle myopathy in humans. Based on these criteria, there is evidence for
myopathy in the Hdh
Q150/Q150 mice. The percentage of angular fibres is within the normal range.
doi:10.1371/journal.pone.0008025.t003
HD Mice: Non-CNS Pathology
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membrane characteristics of denervated or paralysed muscle fibres
[32]. We have shown that the muscle fibres of the HdhQ150
knock-in model, like those of the R6/2 mice contain nuclear
inclusions. The evidence for myopathy in Hdh
Q150/Q150 mice was
greater than in R6/2 as there was a higher frequency of central
nuclei and some split fibres. In support of a mechanism intrinsic to
muscle, a semi professional marathon runner at risk for HD
developed signs of a slowly progressive myopathy with exercise-
induced muscle fatigue, pain, elevated creatine kinase level and
worsening of his running performance many years before the first
signs of chorea were detected [33]. Common gene expression
profiles in skeletal muscle between R6/2 mice, Hdh
Q150/Q150 mice
and HD patients have previously been reported to reflect disease
progression and be consistent with the beginnings of a transition
from fast-twitch to slow twitch muscle fibre types [34]. More
recently, impaired activity of PPARc coactivator 1a (PGC-1a) and
its target genes, important for inducing mitochondrial biogenesis
and in influencing whether muscle contains slow twitch oxidative
or fast twitch glycolytic fibres, has been demonstrated in the
muscle and myoblasts of HD patients and the muscle of N171-
82Q mice [35]. However, there is also evidence to suggest that the
reduction in muscle bulk can occur by through pathogenic events
exogenous to muscle that are either peripherally or centrally
generated. The metabolic profile of plasma from both N171-82Q
mice and HD patients supports a reduction in muscle bulk being
caused by a catabolic state secondary to hypothalamic pathology
[24,36,37] which is known to occur in both mouse models of HD
and HD patients [24,38,39]. In addition, increased plasma
cytokine levels, notably IL6 and TNFa, have been detected in
people who carry the HD mutation 16 years before the predicted
onset of motor symptoms [40] and could contribute to muscle
wasting.
Early-onset cardiovasclular disease is the second leading cause
of death in HD patients [41,42]. The inclusion pathology in the
hearts of both the R6/2 and HdhQ150 models was comparatively
sparse although cardiac dysfunction has been described in R6/2
mice [43]. The formation of polyQ amyloid has been shown to
cause heart failure as transgenic mice that express an 83 residue
long polyQ repeat in cardiomyocytes exhibited reduced cardiac
function and dilation by five months and all died by eight months
[44]. An electrolyte imbalance has been described in the R6/2
mice at 12 weeks of age [24] which could exacerbate cardiac
failure. A detailed analysis of cardiac function in the HdhQ150
knock-in model and in HD patients is warranted.
Pancreatic inclusion pathology has been reported in all of the N-
terminal Htt transgenic HD models: R6/2 mice [15,25,45,46],
R6/1 mice (which express the same exon 1 transgene but at a
lower level) [47] and N171-82Q mice [16] and the presence of
aggregates has been shown to correlate with islet size [16]. A
subset of R6/2 mice develop diabetes, and all R6/2 mice have
impaired glucose homeostasis [45,46,48,49,50], a phenotype that
has also been reported in the R6/1 [47], N171-82Q [16,51] and
HdhQ150 knock-in models [34]. The pancreatic islets of the R6/2
mice have been shown to express reduced levels of the islet
hormones: insulin, somatostatin and glucagon [25,46,48] and
exhibit intrinsic deficits in insulin production [25,46]. R6/2 mice
develop an age-dependent reduction in insulin mRNA production
and diminished expression of key regulators of insulin gene
transcription: PDX-1, E2A, CBP, and p300 [46]. This is paralleled
by a decrease in b-cell mass (possibly caused through a decrease in
b-cell replication), an absence of exocytosis as induced by
membrane depolarization and a dramatic reduction in the number
of secretory vesicles in R6/2 b-cells [25]. A decrease in b-cell mass
has also been described in R6/1 [47] and N171-82Q mice [16].
Further support for the diabetes in the R6/2 mice being caused by
impairment in insulin release rather than insulin insensitivity has
been generated by the administration of pharmacological agents
[45]. In this study, we have shown that inclusions are present in
the pancreatic islet cells of Hdh
Q150/Q150 mice which combined
with previous reports of impaired glucose homeostasis in this
model, suggests that the pancreatic pathology described in the N-
terminal fragment models extends to the HD knock-in models.
However, the inclusion pathology exhibited greater variation
between Hdh
Q150/Q150 mice than in R6/2 and we did not find a
reduction in the number of secretory vesicles in knock-in b-cells.
The extent to which these findings extend to HD patients
currently remains unclear. Impairment in insulin secretion
capacity and a simultaneous decrease in insulin sensitivity, with
an increase in the insulin resistance level was recently reported in
normoglycaemic HD patients [21]. However, in a different study,
the level of insulin transcripts as measured by immunostaining and
the islet b-cell area were similar in HD patients and controls.
Pancreatic islets appeared histologically normal and there was no
sign of amyloid deposition [52].
Many of the peripheral symptoms that have been described in
HD patients and mouse models of HD could be the result of
disturbed hypothalamic-endocrine axes [53]. As mentioned above,
disturbances in the hypothalamic-pituitary-adrenal axis could
contribute to weight loss and there is marked adrenal pathology in
both the R6/2 and Hdh
Q150/Q150 mice. The hypertrophy of the
adrenal cortex and progressive increase in corticosterone levels
could account for reduced bone mineral density, insulin resistance
and muscular atrophy recorded in R6/2 mice [24]. Increased
levels of corticosteroids have been reported in HD patients
[24,53,54], but a recent study dissociated this from weight loss
[54]. Impairments were[54] identified in several anterior pituitary
axes [54]. Both central growth hormone (GH) and peripheral
insulin growth factor-1 (IGF-1) somatotropic hormones were
higher in HD patients, increased with disease progression and
were linked to weight loss, potentially implicating a liver
pathology. Testicular pathology has been described in HD patients
with reduced numbers of germ cells and abnormal seminiferous
tubule morphology [55]. We have shown that the testes are
reduced in size in both R6/2 and Hdh
Q150/Q150 mice, also
reported in the YAC128 HD mouse model [55], and testosterone
levels are reduced in both R6/2 mice [56] and male HD patients
[54,57]. This could arise through a decrease in the production of
gonadotrophin-releasing hormone in the hypothalamus [56], a loss
of the direct neuronal hypothalamic-testicular pathway [54] or the
direct effect of mutant Htt in the testes [55].
Body weight regulation is a highly complex process that involves
the GI tract and adipose tissue in addition to the hypothalamus
and pancreas discussed above [37]. It is governed by the balance
of food intake, energy expenditure and metabolism. Both the R6/
2 mice and HD patients have been shown to have an increased
metabolic rate [36,37]. The hypothalamus integrates peripheral
signals of energy levels and regulates food intake, energy balance
and metabolism. Van der Burg et al. [37] have shown that there
are reduced levels of hypothalamic peptides important for
regulating food intake and metabolism. We have demonstrated
that inclusions are present in the adipocytes of R6/2 and
Hdh
Q150/Q150 mice, a pathology also present in N171-82Q mice
[58]. Adipose tissue-derived hormones that regulate food intake
and glucose metabolism have been shown to be dysregulated in
the R6/2 [50,59] and HdhQ140 knock-in HD models [59],
suggesting an intrinsic adipocyte dysfunction that may contribute
to weight loss. Mutant Htt has been shown to dysregulate gene
HD Mice: Non-CNS Pathology
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including the uncoupling proteins (UCPs) [37,58,59] resulting in
impaired thermogenesis and metabolic abnormalities. As men-
tioned above, PGC-1a activity is also decreased in muscle from
HD patients and N171-82Q mice [35] and given the pathology
that we have described in R6/2 and Hdh
Q150/Q150 liver, an
investigation of the UCPs in liver is warranted. We identified
inclusion pathology throughout the stomach wall and in the plexi
of the stomach, duodenum and rectum. Grehlin, a peptide
produced in the gastric mucosa that stimulates food intake has
been shown to be down-regulated in the R6/2 mice [37]
implicating a direct role for the GI tract in HD pathology.
As peripheral tissues are more accessible than those of the CNS,
the presence of peripheral HD pathologies might lead to
biomarkers that can be used to track disease progression in
therapeutic intervention trials. Whether peripheral clinical bio-
markers for adult onset HD can be identified will depend on the
analysis of patient samples. It is unlikely that inclusion formation in
the peripheral tissues of the HdhQ150 knock-in mice will provide a
useful read-out in preclinical studies as our preliminary analyses
suggest that aggregate formation in the periphery occurs later than
that in brain [60]. However, the peripheral pathologies in the R6/
2 model allow proof of concept studies with potentially disease
modifying therapeutic compounds to be performed without the
initial requirement to cross the blood brain barrier.
We have identified extensive inclusion pathology with a very
similar distribution in two quite different mouse models of HD.
There is mounting evidence to indicate that peripheral pathologies
contribute to phenotypes exhibited by these and other HD mouse
models alongside effects from the CNS. The size of the CAG
repeat expansion in both the R6/2 and HdhQ150 models is of a
size that would cause childhood disease in humans and would be
expected to result in a more widespread pathology than CAG
repeat expansions in the adult onset range. Therefore, although
many peripheral symptoms of adult onset HD have been
documented, the extent to which the peripheral pathology
identified in the mouse models relates to adult onset disease is as
yet unknown. There have been very few studies of the peripheral
pathology in HD organs, largely because post mortem specimens
have not been available for analysis. However, it is very important
that a comprehensive analysis of HD peripheral pathology is
undertaken, both to allow a better mechanistic understanding of
the disease and to inform possible therapeutic interventions that




All animal work was approved by the King’s College London
Ethical Review Panel and performed under Home Office project
and personal licenses.
HD mouse models
Hemizygous R6/2 mice [10] were bred by backcrossing R6/2
males to (CBA x C57Bl/6) F1 females (B6CBAF1/OlaHsd,
Harlan Olac, Bicester, UK). Hdh
Q150/Q150 homozygous knock-in
mice [12,13] on a (CBA x C57Bl/6) F1 background were
generated by intercrossing Hdh
Q150/Q7 heterozygous CBA/Ca
and C57BL/6J congenic lines (inbred lines from Harlan Olac,
Bicester, UK). All animals were subject to a 12 h light/dark cycle,
had unlimited access to water and breeding chow (Special Diet
Services, Witham, UK). Housing conditions and environmental
enrichment were as previously described [29]. R6/2 mice were
always housed with wild type mice. The CAG repeat size in the
R6/2 mouse was 213 and in the Hdh
Q150/Q150 mice was 15563.4
(SD).
Genotyping and CAG repeat sizing
R6/2 and Hdh
Q150/Q150 mice were identified by PCR of tail-tip
DNA. For R6/2, a 10 ml reaction contained 100 ng DNA, 1x
Thermo-Start master mix (Thermo Scientific), 1 ml DMSO,
10 ng/ml forward primer 33727 [59-CGCAGGCTAGGGCTGT-
CAATCATGCT-39], and 10 ng/ml reverse primer 32252 [59-
TCATCAGCTTTTCCAGGGTCGCCAT-39]. Cycling condi-
tions were: 15 min @ 94uC, 356(30 s @ 94uC; 30 s @ 60uC,
60 s @72uC) and 10 min @ 72uC. The amplified R6/2 transgene
product was 272 bp. For Hdh
Q150/Q150 mice, a 20 ml reaction
contained 150 ng tail-tip DNA, 0.1 mM dNTPs, 2 M betaine
(Sigma), 1x Detloff buffer [15 mM Tris–HCl (pH 8.8), 15 mM
Tris–HCl (pH 9.0), 16 mM (NH4)2SO4, 2.5 mM MgCl2,
0.15 mg/ml bovine serum albumin (BSA), 0.007% b-mercapto-
ethanol], 10 ng/ml forward primer MHD16 [59-CCCATT-
CATTGCCTTGCTGCTAGG-39], 10 ng/ml reverse primer
MHD18 [59-GACTCACGGTCGGTGCAGCGGTTCC-39],
and 1 U Herculase Taq polymerase (Stratagene). Amplification
conditions were: 5 min @ 95uC, 306(30 s @ 94uC, 30 s @ 58uC,
3 min @ 72uC) and 5 min @ 72uC. The wild type allele amplified
a 278 bp product whereas the HdhQ150 knock-in allele amplified
a 707 bp product. Amplification of the CAG repeat from R6/2
mouse DNA was performed with a FAM labelled forward primer
(GAGTCCCTCAAGTCCTTCCAGCA) and reverse primer
(GCCCAAACTCACGGTCGGT) in 10 ml reactions containing:
0.2 mM dNTPs; 10% DMSO; AM buffer (67 mM Tris-HCL
pH 8.8; 16.6 mM (NH4)S04; 2 mM MgCl2; 0.17 mg/ml BSA)
and 0.5U AmpliTaq DNA polymerase (Applied Biosystems).
Cycling conditions were: 90 s @ 94uC, 246(30 s @ 94uC; 30 s @
65uC; 90 s @ 72uC) and 10 min @ 72uC. For Hdh
Q150/Q150 mice,
the amplification reaction was as for genotyping (above) with a
FAM labelled reverse MHD18 primer. All instruments and
materials were obtained from Applied Biosystems unless indicated.
The FAM-tagged PCR product (1 ml) together with MegaBA-
CE
TM ET900 (Amersham Bioscience) internal size standard
(0.04 ml) were denatured at 94uC, 5 min in 9 ml of HiDi-
formamide and analyzed using an ABI3730 sequencer. Data
analysis was performed using plate manager application Gene-
Mapper v5.2- 3730XL.
Histology
Peripheral tissues were dissected from, four 22 month old
Hdh
Q150/Q150 mice, four wild type littermate control mice, one 12
week old R6/2 and one wild type littermate control, that had been
perfusion fixed with 4% paraformaldehyde. The organs and tissues
were removed for histological examination and the heart, kidneys,
liver, spleen, quadriceps and testis weighed. Tissues were
processed and embedded in paraffin wax and 5 mm sections were
cut on an RM 2155 microtome (Leica Microsystems). A few
sections from each tissue were stained with Harris’s haematoxylin
and eosin (H&E) [61].
Immunohistochemistry
The remaining sections were immunoperoxidase stained with
huntingtin antibody S830 [62]. Sections were dewaxed in
histoclear (Agar Scientific), rehydrated, incubated in 4% hydrogen
peroxide for 10 mins, washed in dH20, antigen retrieved by
pressure cooking on high in 0.1 M Citric acid pH 6.0 for 7 min
and washed in dH2O [61]. Endogenous biotin was blocked using a
Biotin Blocking kit (Vector Laboratories) and incubated in primary
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(0.1 M Tris-HCl pH 7.5, 0.9% NaCl (TBS) and 2% bovine serum
albumin (BSA)) at 4uC overnight, washed twice in TBS for 15 min
and incubated for 1 h at RT in biotinylated horse anti-goat
secondary antibody (Vector Laboratories) in blocking solution
(1:500). After washing with TBS, sections were incubated in ABC-
HRP complex using the Vectastain Elite ABC kit (Vector
Laboratories) as recommended by the manufacturer and then
incubated with a 0.05% solution 3,3-diaminobezidine (DAB) in
0.1 M Tris–HCl pH 7.5. H2O2 was added to 0.03%, the colour
allowed to develop for 10 min and the slices washed extensively in
dH2O. Sections were counterstained with Methyl Green prior to
viewing on an Axioskop 2 microscope (Zeiss) and images captured
using an Axiocam camera, and Axiovision software (Zeiss).
Morphometry
The H&E stained sections of the quadriceps muscle were
examined and 10 random high power micrographs were taken for
each animal. The images were then processed using Axiovision
v4.6 software and the muscle fiber diameters estimated using the
bound width measurement (minimum diameter).
Electron microscopy
Pancreatic samples from three additional 22 month old
Hdh
Q150/Q150 mice, 3 littermate controls and two 12 week old
R6/2 mice were fixed in 2.5% glutaraldehyde in 0.125 M
phosphate buffer and processed for transmission electron micro-
scopical examination. 60 nm sections were cut and stained with
saturated aqueous uranyl acetate and Reynolds lead citrate [63]
and imaged using a Jeol JEM 1230 transmission electron
microscope.
Statistical analysis
Sample means were compared using the independent samples
Student’s t-test with the statistical package SPSS v 16.
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